Scotiabank Raises Twist Bioscience (NASDAQ:TWST) Price Target to $54.00

Twist Bioscience (NASDAQ:TWST) had its price target hoisted by Scotiabank from $50.00 to $54.00 in a research report sent to investors on Tuesday,Benzinga reports. The firm currently has a sector outperform rating on the stock.

A number of other research firms have also recently commented on TWST. Barclays decreased their price target on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, August 5th. Robert W. Baird lifted their target price on shares of Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a research note on Tuesday. JPMorgan Chase & Co. upped their price target on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research note on Monday, August 5th. Leerink Partners lifted their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research note on Thursday, October 17th. Finally, Evercore ISI upped their target price on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $51.78.

Twist Bioscience Stock Performance

Shares of Twist Bioscience stock opened at $41.32 on Tuesday. The company has a market capitalization of $2.42 billion, a PE ratio of -10.82 and a beta of 1.78. The company has a 50-day simple moving average of $43.99 and a two-hundred day simple moving average of $46.18. Twist Bioscience has a one year low of $23.00 and a one year high of $60.90.

Insiders Place Their Bets

In related news, SVP Paula Green sold 1,057 shares of the business’s stock in a transaction on Monday, November 4th. The stock was sold at an average price of $41.56, for a total value of $43,928.92. Following the sale, the senior vice president now owns 121,013 shares in the company, valued at approximately $5,029,300.28. The trade was a 0.87 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Robert F. Werner sold 1,448 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total value of $64,580.80. Following the transaction, the chief accounting officer now owns 45,620 shares of the company’s stock, valued at $2,034,652. This trade represents a 3.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 98,118 shares of company stock valued at $4,391,151 over the last 90 days. 3.92% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. ProShare Advisors LLC boosted its position in Twist Bioscience by 10.2% in the 1st quarter. ProShare Advisors LLC now owns 14,444 shares of the company’s stock valued at $496,000 after buying an additional 1,336 shares during the period. State Board of Administration of Florida Retirement System grew its stake in Twist Bioscience by 14.8% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 18,649 shares of the company’s stock worth $640,000 after purchasing an additional 2,410 shares in the last quarter. Edgestream Partners L.P. purchased a new stake in Twist Bioscience during the 1st quarter worth about $242,000. American International Group Inc. raised its position in Twist Bioscience by 0.8% in the 1st quarter. American International Group Inc. now owns 28,506 shares of the company’s stock valued at $978,000 after purchasing an additional 213 shares in the last quarter. Finally, PEAK6 Investments LLC boosted its stake in shares of Twist Bioscience by 20.7% in the 1st quarter. PEAK6 Investments LLC now owns 14,000 shares of the company’s stock valued at $480,000 after buying an additional 2,400 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.